Skip to main content

Figure 3.

Figure 3

Survival curves of patients with clinically detectable peritoneal dissemination. Patients who received complete cytoreduction by peritonectomy after neoadjuvant intraperitoneal–systemic chemotherapy survived significantly better than those with residual disease (incomplete cytoreduction group). 2 y.s.r., 2‐year survival rate; MST, median survival time.